{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:11:10Z","timestamp":1793970670806,"version":"4.8.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T00:00:00Z","timestamp":1375228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurosci"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/nrn3549","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T04:21:25Z","timestamp":1375244485000},"page":"626-636","source":"Crossref","is-referenced-by-count":865,"title":["Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies"],"prefix":"10.1038","volume":"14","author":[{"given":"David J.","family":"Irwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.-Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,31]]},"reference":[{"key":"BFnrn3549_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2012","unstructured":"Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nature Rev. Neurol. 9, 13\u201324 (2012).","journal-title":"Nature Rev. Neurol."},{"key":"BFnrn3549_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387\u2013392 (2003).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/brain\/awq059","volume":"133","author":"PA Kempster","year":"2010","unstructured":"Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T. & Lees, A. J. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 133, 1755\u20131762 (2010).","journal-title":"Brain"},{"key":"BFnrn3549_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22, 1689\u20131707 (2007). The Movement Disorder Society Task Force criteria for PDD.","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","volume":"115","author":"G Halliday","year":"2008","unstructured":"Halliday, G., Hely, M., Reid, W. & Morris, J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409\u2013415 (2008). This is one of the largest prospectively followed PD autopsy series; it found that 80% of patients with PD develop dementia after 20 years.","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ana.10219","volume":"51","author":"G Levy","year":"2002","unstructured":"Levy, G. et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. 51, 722\u2013729 (2002).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR8","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","volume":"132","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray, C. H. et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132, 2958\u20132969 (2009).","journal-title":"Brain"},{"key":"BFnrn3549_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","volume":"65","author":"D Muslimovic","year":"2005","unstructured":"Muslimovic, D., Post, B., Speelman, J. D. & Schmand, B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239\u20131245 (2005).","journal-title":"Neurology"},{"key":"BFnrn3549_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/mds.23073","volume":"25","author":"E Rosenthal","year":"2010","unstructured":"Rosenthal, E. et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov. Disord. 25, 1170\u20131176 (2010).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/archneurol.2009.221","volume":"66","author":"RY Lo","year":"2009","unstructured":"Lo, R. Y. et al. Clinical features in early Parkinson disease and survival. Arch. Neurol. 66, 1353\u20131358 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349\u2013356 (2012). The Movement Disorder Society Task Force criteria for PD-MCI.","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bandl.2011.08.007","volume":"120","author":"M Grossman","year":"2012","unstructured":"Grossman, M. et al. Difficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder. Brain Lang. 120, 52\u201360 (2012).","journal-title":"Brain Lang."},{"key":"BFnrn3549_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000256715.13907.d3","volume":"68","author":"CF Lippa","year":"2007","unstructured":"Lippa, C. F. et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812\u2013819 (2007). An in-depth discussion of the clinicopathological overlap between PDD and DLB.","journal-title":"Neurology"},{"key":"BFnrn3549_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","volume":"67","author":"JE Galvin","year":"2006","unstructured":"Galvin, J. E., Pollack, J. & Morris, J. C. Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605\u20131611 (2006).","journal-title":"Neurology"},{"key":"BFnrn3549_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","volume":"9","author":"IG McKeith","year":"2006","unstructured":"McKeith, I. G. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9, 417\u2013423 (2006). In this paper, the DLB Consortium outlines its clinical and neuropathological diagnostic criteria for DLB.","journal-title":"J. Alzheimers Dis."},{"issue":"Suppl. 2","key":"BFnrn3549_CR17","first-page":"93","volume":"64","author":"D Weintraub","year":"2008","unstructured":"Weintraub, D. Dopamine and impulse control disorders in Parkinson's disease. Ann. Neurol. 64 (Suppl. 2), 93\u2013100 (2008).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","volume":"80","author":"D Weintraub","year":"2013","unstructured":"Weintraub, D., Papay, K., Siderowf, A. & Parkinson's Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80, 176\u2013180 (2013).","journal-title":"Neurology"},{"key":"BFnrn3549_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870130605","volume":"13","author":"A Schrag","year":"1998","unstructured":"Schrag, A., Ben-Shlomo, Y., Brown, R., Marsden, C. D. & Quinn, N. Young-onset Parkinson's disease revisited \u2014 clinical features, natural history, and mortality. Mov. Disord. 13, 885\u2013894 (1998).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00415-006-0234-8","volume":"254","author":"D Aarsland","year":"2007","unstructured":"Aarsland, D. et al. The effect of age of onset of PD on risk of dementia. J. Neurol. 254, 38\u201345 (2007).","journal-title":"J. Neurol."},{"key":"BFnrn3549_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1212\/01.WNL.0000158422.41380.82","volume":"64","author":"H Braak","year":"2005","unstructured":"Braak, H., Rub, U., Jansen Steur, E. N., Del Tredici, K. & de Vos, R. A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404\u20131410 (2005).","journal-title":"Neurology"},{"key":"BFnrn3549_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.55.4.539","volume":"55","author":"G Levy","year":"2000","unstructured":"Levy, G. et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 55, 539\u2013544 (2000).","journal-title":"Neurology"},{"key":"BFnrn3549_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic, J. et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529\u20131534 (1990).","journal-title":"Neurology"},{"key":"BFnrn3549_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mds.10280","volume":"17","author":"G Levy","year":"2002","unstructured":"Levy, G. et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov. Disord. 17, 1221\u20131226 (2002).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR25","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease. Science 276, 2045\u20132047 (1997). This study made the landmark discovery of SNCA mutations in PD.","journal-title":"Science"},{"key":"BFnrn3549_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson's disease. Mov. Disord. 27, 831\u2013842 (2012).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton, A. B. et al. \u03b1-synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).","journal-title":"Science"},{"key":"BFnrn3549_CR28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/3311","volume":"4","author":"KA Conway","year":"1998","unstructured":"Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant \u03b1-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318\u20131320 (1998).","journal-title":"Nature Med."},{"key":"BFnrn3549_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997). This study made the landmark discovery of \u03b1-syn as the major component of Lewy pathology.","journal-title":"Nature"},{"key":"BFnrn3549_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson, B. I. et al. Neuronal \u03b1-synucleinopathy with severe movement disorder in mice expressing A53T human \u03b1-synuclein. Neuron 34, 521\u2013533 (2002).","journal-title":"Neuron"},{"key":"BFnrn3549_CR31","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1523\/JNEUROSCI.0618-11.2011","volume":"31","author":"Y Lim","year":"2011","unstructured":"Lim, Y. et al. \u03b1-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 31, 10076\u201310087 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrn3549_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0079-6123(10)84004-X","volume":"184","author":"I Magen","year":"2010","unstructured":"Magen, I. & Chesselet, M. F. Genetic mouse models of Parkinson's disease: the state of the art. Prog. Brain Res. 184, 53\u201387 (2010).","journal-title":"Prog. Brain Res."},{"key":"BFnrn3549_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrn3549_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jnen\/61.5.413","volume":"61","author":"K Del Tredici","year":"2002","unstructured":"Del Tredici, K., Rub, U., De Vos, R. A., Bohl, J. R. & Braak, H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413\u2013426 (2002).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Suppl. 1","key":"BFnrn3549_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mds.22637","volume":"25","author":"DW Dickson","year":"2010","unstructured":"Dickson, D. W., Uchikado, H., Fujishiro, H. & Tsuboi, Y. Evidence in favor of Braak staging of Parkinson's disease. Mov. Disord. 25 (Suppl. 1), 78\u201382 (2010).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-004-0138-7","volume":"111","author":"KA Jellinger","year":"2004","unstructured":"Jellinger, K. A. Lewy body-related \u03b1-synucleinopathy in the aged human brain. J. Neural Transm. 111, 1219\u20131235 (2004).","journal-title":"J. Neural Transm."},{"key":"BFnrn3549_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","volume":"115","author":"L Parkkinen","year":"2008","unstructured":"Parkkinen, L., Pirttila, T. & Alafuzoff, I. Applicability of current staging\/categorization of \u03b1-synuclein pathology and their clinical relevance. Acta Neuropathol. 115, 399\u2013407 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613\u2013634 (2009).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jnen\/64.2.156","volume":"64","author":"I Mikolaenko","year":"2005","unstructured":"Mikolaenko, I. et al. \u03b1-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64, 156\u2013162 (2005).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrn3549_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.20321","volume":"57","author":"L Parkkinen","year":"2005","unstructured":"Parkkinen, L., Kauppinen, T., Pirttila, T., Autere, J. M. & Alafuzoff, I. \u03b1-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol. 57, 82\u201391 (2005).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","volume":"115","author":"DW Dickson","year":"2008","unstructured":"Dickson, D. W. et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115, 437\u2013444 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/jnen\/62.6.644","volume":"62","author":"Y Saito","year":"2003","unstructured":"Saito, Y. et al. Accumulation of phosphorylated \u03b1-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62, 644\u2013654 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrn3549_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495\u2013508 (2013).","journal-title":"Mol. Neurobiol."},{"key":"BFnrn3549_CR44","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","volume":"79","author":"JM Milber","year":"2012","unstructured":"Milber, J. M. et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 79, 2307\u20132314 (2012).","journal-title":"Neurology"},{"key":"BFnrn3549_CR45","first-page":"277","volume":"1","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen, L. et al. Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease. J. Park Dis. 1, 277\u2013286 (2011).","journal-title":"J. Park Dis."},{"key":"BFnrn3549_CR46","first-page":"89","volume":"70","author":"H Braak","year":"2006","unstructured":"Braak, H. et al. Pathology associated with sporadic Parkinson's disease \u2014 where does it end? J. Neural Transm. Suppl. 70, 89\u201397 (2006).","journal-title":"J. Neural Transm. Suppl."},{"key":"BFnrn3549_CR47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton, R. L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry. Brain Pathol. 10, 378\u2013384 (2000).","journal-title":"Brain Pathol."},{"key":"BFnrn3549_CR48","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","volume":"153","author":"CF Lippa","year":"1998","unstructured":"Lippa, C. F. et al. Lewy bodies contain altered \u03b1-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365\u20131370 (1998).","journal-title":"Am. J. Pathol."},{"key":"BFnrn3549_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1440-1789.2003.00530.x","volume":"24","author":"E Iseki","year":"2004","unstructured":"Iseki, E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. Neuropathology 24, 72\u201378 (2004).","journal-title":"Neuropathology"},{"key":"BFnrn3549_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1750-3639.2007.00117.x","volume":"18","author":"JB Leverenz","year":"2008","unstructured":"Leverenz, J. B. et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 18, 220\u2013224 (2008).","journal-title":"Brain Pathol."},{"key":"BFnrn3549_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-008-0406-y","volume":"116","author":"KA Jellinger","year":"2008","unstructured":"Jellinger, K. A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116, 1\u201316 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Med. 14, 501\u2013503 (2008).","journal-title":"Nature Med."},{"key":"BFnrn3549_CR53","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Med. 14, 504\u2013506 (2008).","journal-title":"Nature Med."},{"key":"BFnrn3549_CR54","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/mds.22369","volume":"23","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W. & Freeman, T. B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 23, 2303\u20132306 (2008).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR55","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk, K. C. et al. Exogenous \u03b1-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051\u201320056 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrn3549_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"BFnrn3549_CR57","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J. Exp. Med. 209, 975\u2013986 (2012).","journal-title":"J. Exp. Med."},{"key":"BFnrn3549_CR58","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949\u2013953 (2012). This study made the landmark discovery of how the transmission of \u03b1-syn fibrils alone recapitulates human disease in wild-type animals.","journal-title":"Science"},{"key":"BFnrn3549_CR59","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","volume":"40","author":"HJ Lee","year":"2008","unstructured":"Lee, H. J. et al. Assembly-dependent endocytosis and clearance of extracellular \u03b1-synuclein. Int. J. Biochem. Cell Biol. 40, 1835\u20131849 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrn3549_CR60","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","volume":"106","author":"P Desplats","year":"2009","unstructured":"Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of \u03b1-synuclein. Proc. Natl Acad. Sci. USA 106, 13010\u201313015 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrn3549_CR61","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.neurobiolaging.2011.06.022","volume":"33","author":"AL Mougenot","year":"2012","unstructured":"Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225\u20132228 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrn3549_CR62","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake, M. et al. Prion-like spreading of pathological \u03b1-synuclein in brain. Brain 136, 1128\u20131138 (2013).","journal-title":"Brain"},{"key":"BFnrn3549_CR63","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/cdd.2011.53","volume":"18","author":"JA Steiner","year":"2011","unstructured":"Steiner, J. A., Angot, E. & Brundin, P. A deadly spread: cellular mechanisms of \u03b1-synuclein transfer. Cell Death Differ. 18, 1425\u20131433 (2011).","journal-title":"Cell Death Differ."},{"key":"BFnrn3549_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mds.25373","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow, C. W. & Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov. Disord. 28, 31\u201340 (2013). A timely review of PD model transmission studies.","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neuron.2006.09.026","volume":"52","author":"VM Lee","year":"2006","unstructured":"Lee, V. M. & Trojanowski, J. Q. Mechanisms of Parkinson's disease linked to pathological \u03b1-synuclein: new targets for drug discovery. Neuron 52, 33\u201338 (2006).","journal-title":"Neuron"},{"key":"BFnrn3549_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaneurol.2013.1933","volume":"70","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J. et al. Evaluation of potential infectivity of Alzheimer's and Parkinson's disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70, 462\u2013468 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrn3549_CR67","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","volume":"54","author":"HI Hurtig","year":"2000","unstructured":"Hurtig, H. I. et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916\u20131921 (2000).","journal-title":"Neurology"},{"key":"BFnrn3549_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ana.10279","volume":"52","author":"JE Duda","year":"2002","unstructured":"Duda, J. E., Giasson, B. I., Mabon, M. E., Lee, V. M. & Trojanowski, J. Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52, 205\u2013210 (2002).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archneur.59.1.102","volume":"59","author":"H Apaydin","year":"2002","unstructured":"Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F. & Dickson, D. W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59, 102\u2013112 (2002).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR70","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587\u2013598 (2012). A large autopsy cohort involving multivariate analysis of multiple clinical, genetic and neuropathological variables that implicate Lewy body and neurite pathology as the strongest correlate of PDD.","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR71","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain. 134, 1493\u20131505 (2011).","journal-title":"Brain."},{"issue":"Suppl. 3","key":"BFnrn3549_CR72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1353-8020(08)70005-1","volume":"13","author":"Y Tsuboi","year":"2007","unstructured":"Tsuboi, Y., Uchikado, H. & Dickson, D. W. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat. Disord. 13 (Suppl. 3), 221\u2013224 (2007).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrn3549_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","volume":"115","author":"KA Jellinger","year":"2008","unstructured":"Jellinger, K. A. & Attems, J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 115, 427\u2013436 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004010100390","volume":"102","author":"AJ Harding","year":"2001","unstructured":"Harding, A. J. & Halliday, G. M. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 102, 355\u2013363 (2001).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00401-003-0705-2","volume":"106","author":"E Kovari","year":"2003","unstructured":"Kovari, E. et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol. 106, 83\u201388 (2003).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W. & Roytta, M. \u03b1-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 100, 285\u2013290 (2000).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR77","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.neurobiolaging.2004.10.006","volume":"26","author":"O Pletnikova","year":"2005","unstructured":"Pletnikova, O. et al. A\u03b2 deposition is associated with enhanced cortical \u03b1-synuclein lesions in Lewy body diseases. Neurobiol. Aging 26, 1183\u20131192 (2005).","journal-title":"Neurobiol. Aging"},{"key":"BFnrn3549_CR78","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","volume":"67","author":"C Ballard","year":"2006","unstructured":"Ballard, C. et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67, 1931\u20131934 (2006).","journal-title":"Neurology"},{"key":"BFnrn3549_CR79","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.48.5.413","volume":"48","author":"EK Perry","year":"1985","unstructured":"Perry, E. K. et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 48, 413\u2013421 (1985).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrn3549_CR80","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ana.410130304","volume":"13","author":"PJ Whitehouse","year":"1983","unstructured":"Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 13, 243\u2013248 (1983).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/NEN.0b013e31816362aa","volume":"67","author":"ME Kalaitzakis","year":"2008","unstructured":"Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M. & Pearce, R. K. Striatal \u03b2-amyloid deposition in Parkinson disease with dementia. J. Neuropathol. Exp. Neurol. 67, 155\u2013161 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrn3549_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-211-73574-9_12","volume":"72","author":"KA Jellinger","year":"2007","unstructured":"Jellinger, K. A. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural. Transm. Suppl. 72, 91\u2013104 (2007).","journal-title":"J. Neural. Transm. Suppl."},{"key":"BFnrn3549_CR83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s007020200027","volume":"109","author":"KA Jellinger","year":"2002","unstructured":"Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 109, 329\u2013339 (2002).","journal-title":"J. Neural Transm."},{"key":"BFnrn3549_CR84","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer, P. T. et al. Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia. Arch. Neurol. 69, 1326\u20131331 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR85","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","volume":"50","author":"AJ Hughes","year":"1993","unstructured":"Hughes, A. J., Daniel, S. E., Blankson, S. & Lees, A. J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50, 140\u2013148 (1993).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh, M. N. et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23, 295\u2013297 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrn3549_CR87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","volume":"115","author":"T Lashley","year":"2008","unstructured":"Lashley, T. et al. Cortical \u03b1-synuclein load is associated with amyloid-\u03b2 plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 115, 417\u2013425 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR88","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah, E. et al. \u03b2-amyloid peptides enhance \u03b1-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 12245\u201312250 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrn3549_CR89","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q. & LaFerla, F. M. Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 7281\u20137289 (2010).","journal-title":"J. Neurosci."},{"key":"BFnrn3549_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-002-0563-3","volume":"104","author":"JE Duda","year":"2002","unstructured":"Duda, J. E. et al. Concurrence of \u03b1-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 104, 7\u201311 (2002).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.tins.2004.01.007","volume":"27","author":"VM Lee","year":"2004","unstructured":"Lee, V. M., Giasson, B. I. & Trojanowski, J. Q. More than just two peas in a pod: common amyloidogenic properties of tau and \u03b1-synuclein in neurodegenerative diseases. Trends Neurosci. 27, 129\u2013134 (2004).","journal-title":"Trends Neurosci."},{"key":"BFnrn3549_CR92","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson, B. I. et al. Initiation and synergistic fibrillization of tau and \u03b1-synuclein. Science 300, 636\u2013640 (2003).","journal-title":"Science"},{"key":"BFnrn3549_CR93","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000107703","volume":"4","author":"KA Jellinger","year":"2007","unstructured":"Jellinger, K. A., Wenning, G. K. & Seppi, K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener. Dis. 4, 428\u2013430 (2007).","journal-title":"Neurodegener. Dis."},{"key":"BFnrn3549_CR94","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/WAD.0b013e318199d833","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh, M. N. et al. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis. Assoc. Disord. 23, 229\u2013233 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrn3549_CR95","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-007-0261-2","volume":"114","author":"H Nakashima-Yasuda","year":"2007","unstructured":"Nakashima-Yasuda, H. et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 114, 221\u2013229 (2007).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR96","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jnnp.74.7.852","volume":"74","author":"C Colosimo","year":"2003","unstructured":"Colosimo, C., Hughes, A. J., Kilford, L. & Lees, A. J. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74, 852\u2013856 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrn3549_CR97","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/mds.10274","volume":"17","author":"IH Richard","year":"2002","unstructured":"Richard, I. H., Papka, M., Rubio, A. & Kurlan, R. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov. Disord. 17, 1161\u20131165 (2002).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR98","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00401-006-0088-2","volume":"112","author":"KA Jellinger","year":"2006","unstructured":"Jellinger, K. A. & Attems, J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 112, 253\u2013260 (2006).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR99","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-011-0641-6","volume":"118","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M., Song, Y. J. & Harding, A. J. Striatal \u03b2-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural Transm. 118, 713\u2013719 (2011).","journal-title":"J. Neural Transm."},{"key":"BFnrn3549_CR100","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","volume":"60","author":"AR Merdes","year":"2003","unstructured":"Merdes, A. R. et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60, 1586\u20131590 (2003).","journal-title":"Neurology"},{"key":"BFnrn3549_CR101","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1212\/WNL.53.9.1974","volume":"53","author":"J Verghese","year":"1999","unstructured":"Verghese, J., Crystal, H. A., Dickson, D. W. & Lipton, R. B. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 53, 1974\u20131982 (1999).","journal-title":"Neurology"},{"key":"BFnrn3549_CR102","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.55.7.969","volume":"55","author":"I Litvan","year":"1998","unstructured":"Litvan, I. et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol. 55, 969\u2013978 (1998).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR103","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00415-009-5324-y","volume":"257","author":"PT Nelson","year":"2010","unstructured":"Nelson, P. T. et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J. Neurol. 257, 359\u2013366 (2010).","journal-title":"J. Neurol."},{"key":"BFnrn3549_CR104","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","volume":"64","author":"ML Kraybill","year":"2005","unstructured":"Kraybill, M. L. et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64, 2069\u20132073 (2005).","journal-title":"Neurology"},{"key":"BFnrn3549_CR105","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/mds.23116","volume":"25","author":"SM van Rooden","year":"2010","unstructured":"van Rooden, S. M. et al. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov. Disord. 25, 969\u2013978 (2010).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR106","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/brain\/awp234","volume":"132","author":"M Selikhova","year":"2009","unstructured":"Selikhova, M. et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947\u20132957 (2009).","journal-title":"Brain"},{"key":"BFnrn3549_CR107","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/mds.20897","volume":"21","author":"G Alves","year":"2006","unstructured":"Alves, G., Larsen, J. P., Emre, M., Wentzel-Larsen, T. & Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov. Disord. 21, 1123\u20131130 (2006).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR108","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00702-010-0462-z","volume":"117","author":"H Prikrylova Vranova","year":"2010","unstructured":"Prikrylova Vranova, H. et al. CSF markers of neurodegeneration in Parkinson's disease. J. Neural Transm. 117, 1177\u20131181 (2010).","journal-title":"J. Neural Transm."},{"key":"BFnrn3549_CR109","first-page":"537","volume":"85","author":"G Alves","year":"2012","unstructured":"Alves, G. et al. Cerebrospinal fluid amyloid-\u03b2 and phenotypic heterogeneity in de novo Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 85, 537\u2013543 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrn3549_CR110","unstructured":"Kang, J. H. et al. Association of cerebrospinal fluid A\u03b21-42, t-tau, p-tau181 and \u03b1-synuclein levels with clinical 1 features of early drug na\u00efve Parkinson's disease patients. JAMA Neurol. (in the press)."},{"key":"BFnrn3549_CR111","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mds.25213","volume":"28","author":"ML M\u00fcller","year":"2012","unstructured":"M\u00fcller, M. L. et al. \u03b2-amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov. Disord. 28, 296\u2013301 (2012).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR112","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-011-0852-9","volume":"122","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187\u2013204 (2011).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR113","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","volume":"11","author":"P Svenningsson","year":"2012","unstructured":"Svenningsson, P., Westman, E., Ballard, C. & Aarsland, D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 11, 697\u2013707 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrn3549_CR114","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrn3549_CR115","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","volume":"79","author":"D Tsuang","year":"2012","unstructured":"Tsuang, D. et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79, 1944\u20131950 (2012).","journal-title":"Neurology"},{"key":"BFnrn3549_CR116","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"BFnrn3549_CR117","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls, M. A. et al. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol. 70, 727\u2013735 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrn3549_CR118","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1001\/archneurol.2009.54","volume":"66","author":"LN Clark","year":"2009","unstructured":"Clark, L. N. et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch. Neurol. 66, 578\u2013583 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrn3549_CR119","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mds.24946","volume":"27","author":"JF Morley","year":"2012","unstructured":"Morley, J. F. et al. Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 27, 512\u2013518 (2012).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR120","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang, D. et al. APOE \u03b54 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 70, 223\u2013228 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrn3549_CR121","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00415-009-0119-8","volume":"256","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray, C. H. et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J. Neurol. 256, 493\u2013498 (2009).","journal-title":"J. Neurol."},{"key":"BFnrn3549_CR122","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s004010050824","volume":"95","author":"K Wakabayashi","year":"1998","unstructured":"Wakabayashi, K. et al. Apolipoprotein E \u03b54 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol. 95, 450\u2013454 (1998).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR123","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","volume":"75","author":"A Siderowf","year":"2010","unstructured":"Siderowf, A. et al. CSF amyloid \u03b21\u201342 predicts cognitive decline in Parkinson disease. Neurology 75, 1055\u20131061 (2010).","journal-title":"Neurology"},{"key":"BFnrn3549_CR124","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","volume":"8","author":"M Baker","year":"1999","unstructured":"Baker, M. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711\u2013715 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrn3549_CR125","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ana.21157","volume":"62","author":"CP Zabetian","year":"2007","unstructured":"Zabetian, C. P. et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann. Neurol. 62, 137\u2013144 (2007).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR126","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.21192","volume":"62","author":"A Goris","year":"2007","unstructured":"Goris, A. et al. Tau and \u03b1-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 62, 145\u2013153 (2007).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR127","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2010.10.015","volume":"487","author":"Y Compta","year":"2011","unstructured":"Compta, Y. et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal \u03b2-amyloid in Parkinson disease. Neurosci. Lett. 487, 169\u2013173 (2011).","journal-title":"Neurosci. Lett."},{"key":"BFnrn3549_CR128","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.22271","volume":"69","author":"AS Chen-Plotkin","year":"2011","unstructured":"Chen-Plotkin, A. S. et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann. Neurol. 69, 655\u2013663 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR129","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-012-6648-6","volume":"260","author":"MT Pellecchia","year":"2012","unstructured":"Pellecchia, M. T. et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J. Neurol. 260, 438\u2013444 (2012).","journal-title":"J. Neurol."},{"key":"BFnrn3549_CR130","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/mds.22594","volume":"24","author":"Y Compta","year":"2009","unstructured":"Compta, Y. et al. Cerebrospinal tau, phospho-tau, and \u03b2-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24, 2203\u20132210 (2009).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR131","first-page":"1445","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall, S. et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. JAMA Neurol. 69, 1445\u20131452 (2012).","journal-title":"JAMA Neurol."},{"key":"BFnrn3549_CR132","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/jnnp.2009.199950","volume":"81","author":"G Alves","year":"2010","unstructured":"Alves, G. et al. CSF amyloid-\u03b2 and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080\u20131086 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrn3549_CR133","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine, T. J. et al. CSF A\u03b242 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682\u20132685 (2010).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR134","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.parkreldis.2010.10.003","volume":"17","author":"JB Leverenz","year":"2011","unstructured":"Leverenz, J. B. et al. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17, 61\u201364 (2011).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrn3549_CR135","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer, B. et al. Direct quantification of CSF \u03b1-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315\u2013325 (2008).","journal-title":"Exp. Neurol."},{"key":"BFnrn3549_CR136","first-page":"121ra20","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. Phosphorylated \u03b1-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra20 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrn3549_CR137","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda, T. et al. Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766\u20131772 (2010).","journal-title":"Neurology"},{"key":"BFnrn3549_CR138","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong, Z. et al. DJ-1 and \u03b1-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713\u2013726 (2010).","journal-title":"Brain"},{"key":"BFnrn3549_CR139","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.22311","volume":"69","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570\u2013580 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR140","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.parkreldis.2012.04.028","volume":"18","author":"Y Compta","year":"2012","unstructured":"Compta, Y. et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat. Disord. 18, 941\u2013947 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrn3549_CR141","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/brain\/awr277","volume":"135","author":"D Weintraub","year":"2011","unstructured":"Weintraub, D. et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 135, 170\u2013180 (2011).","journal-title":"Brain"},{"key":"BFnrn3549_CR142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","volume":"80","author":"SN Gomperts","year":"2013","unstructured":"Gomperts, S. N. et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80, 85\u201391 (2013).","journal-title":"Neurology"},{"key":"BFnrn3549_CR143","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1212\/WNL.0b013e3182698d4a","volume":"79","author":"M Petrou","year":"2012","unstructured":"Petrou, M. et al. A\u03b2-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79, 1161\u20131167 (2012).","journal-title":"Neurology"},{"key":"BFnrn3549_CR144","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2967\/jnumed.111.089946","volume":"52","author":"NI Bohnen","year":"2011","unstructured":"Bohnen, N. I. et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J. Nucl. Med. 52, 848\u2013855 (2011).","journal-title":"J. Nucl. Med."},{"key":"BFnrn3549_CR145","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/mds.25282","volume":"28","author":"MK Beyer","year":"2013","unstructured":"Beyer, M. K. et al. Cerebrospinal fluid A\u03b2 levels correlate with structural brain changes in Parkinson's disease. Mov. Disord. 28, 302\u2013310 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR146","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek, K. et al. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629\u2013635 (2011).","journal-title":"Prog. Neurobiol."},{"key":"BFnrn3549_CR147","first-page":"CD006504","volume":"3","author":"M Rolinski","year":"2012","unstructured":"Rolinski, M., Fox, C., Maidment, I. & McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst. Rev. 3, CD006504 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 3","key":"BFnrn3549_CR148","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi, K. et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), 42\u201380 (2011).","journal-title":"Mov. Disord."},{"key":"BFnrn3549_CR149","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nature Rev. Neurosci. 14, 38\u201348 (2013). A recent review highlighting the pathophysiology of \u03b1-syn toxicity in PD and potential therapeutic strategies.","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrn3549_CR150","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","volume":"138","author":"E Valera","year":"2013","unstructured":"Valera, E. & Masliah, E. Immunotherapy for neurodegenerative diseases: focus on \u03b1-synucleinopathies. Pharmacol. Ther. 138, 311\u2013322 (2013).","journal-title":"Pharmacol. Ther."},{"key":"BFnrn3549_CR151","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrn3549_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"BFnrn3549_CR153","first-page":"245","volume":"53","author":"CD Ward","year":"1990","unstructured":"Ward, C. D. & Gibb, W. R. Research diagnostic criteria for Parkinson's disease. Adv. Neurol. 53, 245\u2013249 (1990).","journal-title":"Adv. Neurol."},{"key":"BFnrn3549_CR154","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136\u2013144 (1982).","journal-title":"Science"},{"key":"BFnrn3549_CR155","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.expneurol.2009.09.016","volume":"220","author":"JH Kordower","year":"2009","unstructured":"Kordower, J. H. & Brundin, P. Propagation of host disease to grafted neurons: accumulating evidence. Exp. Neurol. 220, 224\u2013225 (2009).","journal-title":"Exp. Neurol."},{"key":"BFnrn3549_CR156","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ana.410350504","volume":"35","author":"P Brown","year":"1994","unstructured":"Brown, P. et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 35, 513\u2013529 (1994).","journal-title":"Ann. Neurol."},{"key":"BFnrn3549_CR157","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJM198509193131205","volume":"313","author":"P Brown","year":"1985","unstructured":"Brown, P., Gajdusek, D. C., Gibbs, C. J. Jr & Asher, D. M. Potential epidemic of Creutzfeldt\u2013Jakob disease from human growth hormone therapy. N. Engl. J. Med. 313, 728\u2013731 (1985).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrn3549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrn3549","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrn3549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:23:26Z","timestamp":1684455806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrn3549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,31]]},"references-count":157,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFnrn3549"],"URL":"https:\/\/doi.org\/10.1038\/nrn3549","relation":{},"ISSN":["1471-003X","1471-0048"],"issn-type":[{"value":"1471-003X","type":"print"},{"value":"1471-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,31]]}}}